NEW YORK, May 30 /PRNewswire/ -- With the advent of a possible new
 blockbuster drug and greater reimbursement levels for the treatment of
 nicotine, alcohol, and drug addictions, global sales of smoking cessation
 and addiction treatments are expected to rise from revenues of little over
 $1.1 billion in 2005 to more than $2.3 billion in 2010, according to
 Smoking Cessation and Addiction Treatments: A World Market Analysis, a new
 study released today from Kalorama Information.
     Nicotine is clearly the most abused drug worldwide, with over 1.4
 billion incidences, including 50 million users in the U.S. alone. Smoking
 cessation has continually become a particular focus of global health
 agencies, and the increasing high awareness of effective smoking cessation
 products have helped to drive market growth.
     The market now dominated by GlaxoSmithKline with its Zyban smoking
 cessation treatment, and Schering-Plough / Reckitt Benckiser with their
 Suboxone/Subetex substance abuse treatment, is primed for a dramatic change
 as Pfizer moves into smoking cessation.
     "We believe Pfizer's Chantix will acquire the largest share of the
 market, overtaking GlaxoSmithKline in smoking cessation, and leading all
 addiction treatments based on the superior effectiveness of Pfizer's
 product in clinical studies," notes Melissa Elder, the report's author. "To
 a more limited extent, new drugs in alcohol and substance abuse treatments
 will also change those markets."
     Smoking Cessation and Addiction Treatments: A World Market Analysis
 includes world incidence and data for nicotine addiction, drug addiction,
 and alcohol abuse; current and forecasted revenues through 2010; current
 and forecasted market share with consideration of new players in the
 market; reviews of current products and new products in the pipeline; and
 key trends driving pharmaceutical treatments for smoking cessation and
 drug/alcohol addiction. It can be purchased directly from Kalorama
 Information by visiting
 http://www.kaloramainformation.com/Smoking-Cessation-Addiction-1460041. It
 is also available at MarketResearch.com.
     About Kalorama Information
     Kalorama Information, a division of MarketResearch.com, supplies the
 latest in independent market research on medical markets. For more
 information, contact Tom Ehart at 240-747-3014 or
 tehart@marketresearch.com, or visit www.KaloramaInformation.com.
     Contact:
     Tom Ehart
     MarketResearch.com
     240-747-3014
     tehart@marketresearch.com
 
 

SOURCE Kalorama Information

Back to top